Ann: COVID ARDS Trial Topline 60-Day Results, page-1538

First 1538 Last

Share
Profile

Follow
Cato

7,294 Posts.

564

08/07/21

17:17

Post #: 54377903
Share

Originally posted by bedger: ↑

The American media and markets particularly seem to be ignoring the 2-3,000 deaths they still have a week from C-19 and the pressing delta variant dangers. Some figures from the English health authority study:

Fully vaccinated, efficacy in the Pfizer vaccine is 94% for the Alpha variant and 88% against the Delta variant. Fully vaccinated with the AstraZeneca vaccine, efficacy is 74% for the Alpha variant and 67% for the Delta variant. The delta variant is around 60% transmissable than the Aplha variant. It doubles the likelihood of hospitalization in non-vaccinated cases. Effectiveness against hospital admission was 92% in AstraZenica and 96% in the case of Pfizer.

It all sounds very positve, but the problem with all these percentage comparisons is they are against unvaccinated data. We need base figures. A more telling figure is that of 806 people admitted to hospital with the delta variant of the virus shown in the study, 84 of the 806 were fully vaccinated and 195 had one dose. It very difficult to get accurate infection rates, hospitalization rates, etc. But the number of delta hospitalizations doubled in weeks and it seems pretty clear that even in well vaccinated countries there are still going to be plenty of hospitalizations with COVID-19 alas, particularly in evolving strains like the Delta variant.

Its very clear there will still be a marginal, but not insignificant number of people critically contracting COVID-19 cases. Whilst the mainstream media may think full vaccination is simply the answer overseas, those of us looking at the data can see there is clearly still a very pressing need for treatments like MSB's Remestemcel-L in a pandemic that will persist in killing people even if they achieved 100% vaccination.

Expand

Hi Bedger,

Sorry, but I think u are not updated.
The Israeli search published 2 days ago shows Pfizer vaccine is good for just 64% in the Delta variation (not 88% as u stated)

Am i wrong ?

CATO

MSB Price at posting: $2.05 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

BM8

Battery Age Minerals gets set to capitalise on critical mineral demand

ASX Market Update: Index pulls back from record highs | October 16, 2024

JBY

James Bay latest lithium player to pivot to other metals amidst lithium slump

PME

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

There are more pages in this discussion • 91 more messages in this thread...

First 1538 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.38		Change -0.080(5.50%)		Mkt cap ! $1.569B

Open	High	Low	Value	Volume
$1.43	$1.43	$1.37	$5.321M	3.829M

Buyers (Bids)

No.	Vol.	Price($)
4	12214	$1.38

Sellers (Offers)

Price($)	Vol.	No.
$1.38	37660	5

View Market Depth

No.	Vol.	Price($)
4	12214	1.375
7	53796	1.370
7	53347	1.365
14	192096	1.360
3	45165	1.355

Price($)	Vol.	No.
1.380	37660	5
1.385	25000	1
1.390	56973	4
1.395	31284	2
1.400	146999	10

Last trade - 16.10pm 16/10/2024 (20 minute delay)

MSB (ASX) Chart

Ann: COVID ARDS Trial Topline 60-Day Results, page-1538

Battery Age Minerals gets set to capitalise on critical mineral demand

ASX Market Update: Index pulls back from record highs | October 16, 2024

James Bay latest lithium player to pivot to other metals amidst lithium slump

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: COVID ARDS Trial Topline 60-Day Results, page-1538

Top Stories

Battery Age Minerals gets set to capitalise on critical mineral demand

ASX Market Update: Index pulls back from record highs | October 16, 2024

James Bay latest lithium player to pivot to other metals amidst lithium slump

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News